New Launch15 Jan 2026, 11:01 pm
Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
AI Summary
Sun Pharmaceutical Industries Limited has announced the availability of UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults in the U.S. with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. UNLOXCYT offers a balanced treatment approach with long-term data confirming durable efficacy and a proven tolerability profile. It has a multifaceted mechanism of action that helps restore the adaptive immune response and engages the innate immune system while preserving PD-L2 signaling.
Key Highlights
- Sun Pharma announces the availability of UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
- UNLOXCYT offers a balanced treatment approach with long-term data confirming durable efficacy and a proven tolerability profile.
- UNLOXCYT has a multifaceted mechanism of action that helps restore the adaptive immune response and engages the innate immune system while preserving PD-L2 signaling.
- UNLOXCYT is now available in the U.S. for healthcare professionals to prescribe.
- Sun Pharma is committed to ensuring access from day one with the UNLOXCYT SUPPORT™ patient access and affordability program.